GlassScriptPhysician profile
Geneva Addison
NPI 1649914680
$2,197.80
in general payments reported to CMS, 2019-2025
21 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.94 · 2023: $284 · 2024: $871 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $352.04 | 2023-2025 | Mavyret, Synthroid |
| Amgen INC. | $315.06 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $302.39 | 2023-2025 | Farxiga, Airsupra |
| Insulet Corporation | $175.25 | 2024-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $127.10 | 2022-2024 | |
| Corcept Therapeutics | $125.81 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $68.21 | 2023-2025 | |
| Esperion Therapeutics, INC. | $52.00 | 2025 | Nexletol |
| Lilly USA, LLC | $43.56 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Shield Therapeutics INC | $42.65 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $38.39 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.52 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $32.76 | 2025 | Auvelity |
| Pfizer INC. | $19.37 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.50 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $16.48 | 2023 | Freestyle Libre 3 |
| Abiomed | $16.31 | 2025 | |
| Merck Sharp & Dohme LLC | $16.05 | 2025 | Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $12.20 | 2025 | Voquezna |
| Cvrx, INC. | $9.81 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Addison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.